÷´Ü Ä¡·áÁ¦ CDMO ½ÃÀå - ¼¼°è »ê¾÷ ±Ô¸ð, Á¡À¯À², µ¿Çâ, ±âȸ, ¿¹Ãø : Á¦Ç°º°, ´Ü°èº°, ÀûÀÀÁõº°, Áö¿ªº°, °æÀﺰ(2020-2030³â)
Advanced Therapy Medicinal Products CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Phase, By Indication, By Region and Competition, 2020-2030F
»óǰÄÚµå : 1668080
¸®¼­Ä¡»ç : TechSci Research
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 180 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,511,000
Unprintable PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 5,500 £Ü 7,957,000
PDF and Excel (Multi-User License) help
PDF ¹× Excel º¸°í¼­¸¦ ±â¾÷ÀÇ ÆÀÀ̳ª ±â°ü¿¡¼­ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ¹× Excel ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,000 £Ü 11,575,000
PDF and Excel (Custom Research License) help
PDF ¹× Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ¹× Excel ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù. 80½Ã°£ÀÇ ¾Ö³Î¸®½ºÆ® ŸÀÓÀÌ Æ÷ÇԵǾî ÀÖ°í Copy & Paste °¡´ÉÇÑ PPT ¹öÀüµµ Á¦°øµË´Ï´Ù. ªÀº Bespoke ¸®¼­Ä¡ ÇÁ·ÎÁ§Æ® ¼öÇà¿¡ ¸Â´Â ¶óÀ̼±½ºÀÔ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

÷´Ü Ä¡·áÁ¦ CDMO ¼¼°è ½ÃÀå ±Ô¸ð´Â 2024³â 51¾ï 2,000¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È 9.54%ÀÇ CAGR·Î 2030³â¿¡´Â 88¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

÷´Ü Ä¡·áÁ¦ CDMO ¼¼°è ½ÃÀåÀº Á¦¾à ¹× »ý¸í°øÇÐ »ê¾÷¿¡¼­ °¡Àå ¿ªµ¿ÀûÀÌ°í ºü¸£°Ô ¹ßÀüÇϰí ÀÖ´Â ºÐ¾ßÀÔ´Ï´Ù. ÀÌ ½ÃÀå¿¡´Â À¯ÀüÀÚ Ä¡·áÁ¦, ¼¼Æ÷ Ä¡·áÁ¦, Á¶Á÷°øÇÐ Á¦Ç° µîÀ» Æ÷ÇÔÇÑ Ã·´ÜÄ¡·áÁ¦(ATMP)ÀÇ °³¹ß ¹× Á¦Á¶¸¦ Àü¹®À¸·Î ÇÏ´Â Á¶Á÷ÀÌ Æ÷ÇԵ˴ϴÙ.

½ÃÀå °³¿ä
¿¹Ãø ±â°£ 2026-2030³â
½ÃÀå ±Ô¸ð : 2024³â 51¾ï 2,000¸¸ ´Þ·¯
½ÃÀå ±Ô¸ð : 2030³â 88¾ï 7,000¸¸ ´Þ·¯
CAGR : 2025-2030³â 9.54%
±Þ¼ºÀå ºÎ¹® Á¾¾çÇÐ
ÃÖ´ë ½ÃÀå ºÏ¹Ì

½ÃÀå ÃËÁø¿äÀÎ

÷´Ü Ä¡·áÁ¦ º¸±Þ

ÁÖ¿ä ½ÃÀå °úÁ¦

³ôÀº ºñ¿ë

ÁÖ¿ä ½ÃÀå µ¿Çâ

Çù¾÷°ú ÆÄÆ®³Ê½Ê Áõ°¡

¸ñÂ÷

Á¦1Àå °³¿ä

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå °í°´ÀÇ ¼Ò¸®

Á¦5Àå ¼¼°èÀÇ Ã·´Ü Ä¡·áÁ¦ CDMO ½ÃÀå Àü¸Á

Á¦6Àå ºÏ¹ÌÀÇ Ã·´Ü Ä¡·áÁ¦ CDMO ½ÃÀå Àü¸Á

Á¦7Àå À¯·´ÀÇ Ã·´Ü Ä¡·áÁ¦ CDMO ½ÃÀå Àü¸Á

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Ã·´Ü Ä¡·áÁ¦ CDMO ½ÃÀå Àü¸Á

Á¦9Àå ³²¹ÌÀÇ Ã·´Ü Ä¡·áÁ¦ CDMO ½ÃÀå Àü¸Á

Á¦10Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ Ã·´Ü Ä¡·áÁ¦ CDMO ½ÃÀå Àü¸Á

Á¦11Àå ½ÃÀå ¿ªÇÐ

Á¦12Àå ½ÃÀå µ¿Çâ°ú ¹ßÀü

Á¦13Àå Porter's Five Forces ºÐ¼®

Á¦14Àå °æÀï ±¸µµ

Á¦15Àå Àü·«Àû Á¦¾È

Á¦16Àå Á¶»ç ȸ»ç ¼Ò°³ ¹× ¸éÃ¥»çÇ×

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Advanced Therapy Medicinal Products CDMO Market was valued at USD 5.12 Billion in 2024 and is expected to reach USD 8.87 Billion by 2030 with a CAGR of 9.54% during the forecast period. The Global Advanced Therapy Medicinal Products CDMO Market is a dynamic and rapidly evolving sector within the pharmaceutical and biotechnology industries. This market encompasses organizations that provide specialized services for the development and manufacturing of advanced therapy medicinal products (ATMPs), which include gene therapies, cell therapies, and tissue-engineered products.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 5.12 Billion
Market Size 2030USD 8.87 Billion
CAGR 2025-20309.54%
Fastest Growing SegmentOncology
Largest MarketNorth America

Key Market Drivers

Proliferation of Advanced Therapies

The healthcare landscape is witnessing a revolution as advanced therapies, including gene therapies, cell therapies, and tissue-engineered products, emerge as groundbreaking treatments for previously incurable diseases. This paradigm shift in medicine is driving the demand for specialized services provided by Contract Development and Manufacturing Organizations (CDMOs).

The advent of advanced therapies has expanded therapeutic horizons, offering new hope to patients suffering from rare and debilitating conditions. These therapies target the root causes of diseases at the genetic and cellular levels, promising higher efficacy and fewer side effects compared to traditional treatments. As more conditions become treatable through advanced therapies, the demand for CDMO services to develop and manufacture these products increases.

Pharmaceutical companies, biotechnology firms, and academic institutions are investing heavily in advanced therapy research and development. This surge in investment translates into a growing pipeline of potential therapies. CDMOs are integral to this process, providing the expertise and infrastructure needed to advance these therapies from the laboratory to clinical trials and eventual commercialization.

The development and manufacturing of advanced therapies come with complex regulatory challenges. Regulatory bodies like the FDA and EMA have stringent requirements to ensure the safety and efficacy of these novel treatments. CDMOs specializing in advanced therapies possess the regulatory expertise to help clients navigate this intricate landscape, ensuring compliance throughout the product lifecycle. This support streamlines the regulatory approval process, accelerating market entry.

Key Market Challenges

High Costs

The development and manufacturing of advanced therapies, such as ATMPs (Advanced Therapy Medicinal Products), are inherently resource-intensive. These therapies require significant investment in research and development, with cutting-edge technology and highly specialized expertise necessary for their creation. The costs associated with preclinical and clinical trials, regulatory approvals, and the production of these therapies can often be prohibitively high, which poses a challenge for Contract Development and Manufacturing Organizations (CDMOs) involved in the production process. Furthermore, the advanced nature of these products demands high-quality standards, specialized facilities, and skilled personnel to ensure safety, efficacy, and compliance with stringent regulations. CDMOs must find innovative ways to streamline production processes, optimize resource allocation, and implement cost-control strategies without compromising the quality of the therapies being developed. Balancing cost efficiency while meeting the demands for high-end manufacturing processes is a critical challenge in the ATMP sector, and finding sustainable solutions is key to ensuring the long-term success of these products.

Key Market Trends

Increased Collaboration and Partnerships

Collaboration is increasingly becoming a critical driver of innovation within the Advanced Therapy Medicinal Product (ATMP) sector. As the complexity and scope of these therapies continue to grow, Contract Development and Manufacturing Organizations (CDMOs) are recognizing the importance of strategic partnerships with pharmaceutical companies, biotech startups, and academic institutions. These alliances allow stakeholders to pool resources, share knowledge, and co-develop cutting-edge therapies that may otherwise be challenging to create independently. In February 2022, Recipharm AB successfully finalized its acquisition of Vibalogics. Through this arrangement, Recipharm is set to gain valuable expertise in biologics, harnessing Vibalogics' capabilities in areas such as viral vaccines, oncolytic viruses, and gene treatments using viral vectors. This strategic move is expected to provide Recipharm with a substantial diversification of its offerings across various technologies and modalities.

Key Market Players

Report Scope:

In this report, the Global Advanced Therapy Medicinal Products CDMO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Advanced Therapy Medicinal Products CDMO Market, By Product:

Advanced Therapy Medicinal Products CDMO Market, By Phase:

Advanced Therapy Medicinal Products CDMO Market, By Indication:

Advanced Therapy Medicinal Products CDMO Market, By Region:

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Advanced Therapy Medicinal Products CDMO Market.

Available Customizations:

Global Advanced Therapy Medicinal Products CDMO market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Advanced Therapy Medicinal Products CDMO Market Outlook

6. North America Advanced Therapy Medicinal Products CDMO Market Outlook

7. Europe Advanced Therapy Medicinal Products CDMO Market Outlook

8. Asia-Pacific Advanced Therapy Medicinal Products CDMO Market Outlook

9. South America Advanced Therapy Medicinal Products CDMO Market Outlook

10. Middle East and Africa Advanced Therapy Medicinal Products CDMO Market Outlook

11. Market Dynamics

12. Market Trends & Developments

13. Porter's Five Forces Analysis

14. Competitive Landscape

15. Strategic Recommendations

16. About Us & Disclaimer

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â